Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
- October-December Generic Share Down 1.3 Points from Prior Qtr: JGA
March 27, 2015
- 15 Drug Makers to Jointly Purchase 150,000 Compounds for Compound Libraries Over 5-Year Period Starting in FY2015
March 27, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
- JPMA to Begin Operating New Statistical Drug Database in FY2015
March 23, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
- JPWA Calls on MHLW to Narrow Down Range of Pharmacies Subjected to Medical Fee Cut Rule for Low Price Settlement Rates
March 20, 2015
- Kyokai Kenpo Aims to Increase Generic Usage Rate to 65.1%
March 20, 2015
- JHSF Calls for Tax Incentives to Promote Investment in Regenerative Medicine
March 19, 2015
- Majority of Doctors Dissatisfied with Existing Treatments for AD, Pancreatic Cancer: JHSF
March 18, 2015
- Bone-Forming Agents Most Needed for Osteoporosis in 2025: JHSF Survey
March 18, 2015
- JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
- Medwatcher Accuses HPV Vaccine Makers of Violating JPMA’s Promotion Code
March 2, 2015
- JPMA to Inform Medical Institutions of New R&D Cost Disclosure Plan in April
February 20, 2015
- AJMC Announces Guidelines for Investigator-Led Clinical Trials
February 20, 2015
- PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan
February 6, 2015
- Number of Contract Sales Reps Increased to 4,148 as of Oct. 2014: CSO Association
February 4, 2015
- JPWA President Reiterates Opposition to Annual NHI Price Revisions
February 2, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…